Synopsis:
Infliximab maintenance therapy could reduce pain and disease activity in hidradenitis suppurativa, according to a study published in Journal of the American Academy of Dermatology.
“Physicians should be using infliximab as the standard for treating hidradenitis suppurativa,” study co-author Steven R. Cohen, MD, MPH, told Healio. “A large percentage of patients with HS have obesity as a comorbidity. When you are dealing with that, you really need a drug that is weight-based.”
The prospective analysis included 42 patients who received an induction dose of infliximab 7.5 mg/kg at weeks 0, 2 and 6, with a maintenance dose of 7.5 mg/kg every 4 weeks thereafter. In a second cohort, 16 patients who did not experience sufficient disease control after the induction dose received a dose escalation of infliximab 10 mg/kg.
Full Research Link:
Full Research Circulation Link: